Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
H Döhner, E Estey, D Grimwade… - Blood, The Journal …, 2017 - ashpublications.org
The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
T Murphy, KWL Yee - Expert opinion on pharmacotherapy, 2017 - Taylor & Francis
Introduction: Acute myeloid leukemia (AML) is the most common acute forms of leukemia in
adults. It has a poor long-term survival with a high relapse rate and at relapse, is commonly …
adults. It has a poor long-term survival with a high relapse rate and at relapse, is commonly …
Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology
MR O'Donnell, MS Tallman, CN Abboud… - Journal of the National …, 2017 - jnccn.org
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults
and accounts for the largest number of annual deaths due to leukemias in the United States …
and accounts for the largest number of annual deaths due to leukemias in the United States …
Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure
M Wattad, D Weber, K Doehner, J Krauter, VI Gaidzik… - Leukemia, 2017 - nature.com
We evaluated the impact of salvage regimens and allogeneic hematopoietic cell
transplantation (allo-HCT) in acute myeloid leukemia (AML) with induction failure. Between …
transplantation (allo-HCT) in acute myeloid leukemia (AML) with induction failure. Between …
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio
J Versluis, R Devillier, WLJ Van Putten, MG Manz… - Leukemia, 2017 - nature.com
Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid
leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with …
leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with …
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia
BACKGROUND Fludarabine and clofarabine are purine nucleoside analogues with
established clinical activity in patients with acute myeloid leukemia (AML). METHODS …
established clinical activity in patients with acute myeloid leukemia (AML). METHODS …
Copy-number analysis identified new prognostic marker in acute myeloid leukemia
O Nibourel, S Guihard, C Roumier, N Pottier, C Terre… - Leukemia, 2017 - nature.com
Recent advances in genomic technologies have revolutionized acute myeloid leukemia
(AML) understanding by identifying potential novel actionable genomic alterations …
(AML) understanding by identifying potential novel actionable genomic alterations …
Randomized phase II study of clofarabine-based consolidation for younger adults with acute myeloid leukemia in first remission
X Thomas, S de Botton, S Chevret, D Caillot… - Journal of Clinical …, 2017 - ascopubs.org
Purpose To evaluate the efficacy and safety of a clofarabine-based combination (CLARA)
versus conventional high-dose cytarabine (HDAC) as postremission chemotherapy in …
versus conventional high-dose cytarabine (HDAC) as postremission chemotherapy in …
[HTML][HTML] Clonal evolution in therapy-related neoplasms
E Fabiani, G Falconi, L Fianchi, M Criscuolo, T Ottone… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Therapy-related myeloid neoplasms (t-MN) may occur as a late effect of cytotoxic therapy for
a primary malignancy or autoimmune diseases in susceptible individuals. We studied the …
a primary malignancy or autoimmune diseases in susceptible individuals. We studied the …
[HTML][HTML] Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents
JE Park, D Hymel, TR Burke Jr, KS Lee - F1000Research, 2017 - ncbi.nlm.nih.gov
Although significant levels of side effects are often associated with their use, microtubule-
directed agents that primarily target fast-growing mitotic cells have been considered to be …
directed agents that primarily target fast-growing mitotic cells have been considered to be …